APOE and Alzheimer disease: However, secondary analysis of fast progressing (APOE4 carriers) and slow progressing AD subgroups revealed a dose-dependent improvement in ADAS-Cog13 and MMSE in the slow progressing subgroup (Ostrowitzki et al., 2017).